A detailed history of Tower Research Capital LLC (Trc) transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 1,793 shares of AADI stock, worth $5,379. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,793
Previous 13,668 86.88%
Holding current value
$5,379
Previous $19,000 84.21%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.32 - $2.06 $15,675 - $24,462
-11,875 Reduced 86.88%
1,793 $3,000
Q2 2024

Aug 13, 2024

BUY
$1.46 - $2.31 $14,846 - $23,490
10,169 Added 290.63%
13,668 $19,000
Q1 2024

May 15, 2024

SELL
$1.59 - $2.44 $2,817 - $4,323
-1,772 Reduced 33.62%
3,499 $8,000
Q4 2023

Feb 13, 2024

SELL
$1.97 - $5.41 $22,320 - $61,295
-11,330 Reduced 68.25%
5,271 $10,000
Q3 2023

Nov 14, 2023

BUY
$4.84 - $7.13 $72,992 - $107,527
15,081 Added 992.17%
16,601 $80,000
Q2 2023

Aug 14, 2023

BUY
$6.84 - $8.56 $2,681 - $3,355
392 Added 34.75%
1,520 $10,000
Q1 2023

May 09, 2023

SELL
$6.85 - $13.0 $23,892 - $45,344
-3,488 Reduced 75.56%
1,128 $8,000
Q4 2022

Feb 10, 2023

SELL
$11.99 - $14.5 $22,133 - $26,767
-1,846 Reduced 28.57%
4,616 $60,000
Q3 2022

Nov 10, 2022

BUY
$12.03 - $14.22 $28,968 - $34,241
2,408 Added 59.4%
6,462 $91,000
Q2 2022

Aug 15, 2022

BUY
$11.57 - $17.92 $30,162 - $46,717
2,607 Added 180.17%
4,054 $50,000
Q1 2022

May 12, 2022

BUY
$16.65 - $24.97 $21,262 - $31,886
1,277 Added 751.18%
1,447 $25,000
Q4 2021

Feb 14, 2022

BUY
$19.32 - $29.02 $2,511 - $3,772
130 Added 325.0%
170 $4,000
Q3 2021

Nov 15, 2021

BUY
$25.52 - $41.85 $1,020 - $1,674
40 New
40 $1,000

Others Institutions Holding AADI

About Aadi Bioscience, Inc.


  • Ticker AADI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 21,016,800
  • Market Cap $63.1M
  • Description
  • Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...
More about AADI
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.